Printer Friendly

Comprehensive Patent Overview of Adenosine A2A Receptor Agonists - Discover Who is Citing your Patents Most Frequently.

DUBLIN, Ireland -- Research and Markets ( has announced the addition of Patent Analysis of Adenosine A2A Receptor Agonists to their offering.

This is a competitive intelligence report of Adenosine A2A Agonists utilizing patent analysis. Extensive patent mining techniques were utilized to produce a base patent set of 202. This base set was then organized and analyzed for competitive intelligence. It has been reported that 75% of the information in patent documents is not available elsewhere. Therefore, this report provides valuable non-scientific literature data organized for actionable intelligence.

The data from this report was collected through October 2004. The patent databases utilized were the USPTO (United States Patent and Trademark Office), EPO (European Patent Office), WIPO (World Intellectual Property Organization), DPMA (German Patent and Trade Mark Office) and the JPO (Japan Patent Office).


--Comprehensive patent overview of Adenosine A2A receptor agonists

--Backward and Forward Citation Maps

--Innovation Speed and Patent Strength Indicators

--Patent Distribution Charts of each company

This report will give you an overview of major and minor players in the field. It enables you to assess your position in this area of research and discover potential acquisition targets. From reading this report you will learn the "Patent Strengths" of key patents.

Discover who is citing your patents most frequently through cluster maps and who the key employees in a particular organization are with this analysis.

Designed for:

--Competitive Intelligence Analysts

--Patent Information Professionals

--Research Scientists

--Patent Attorneys

--Corporate Management

--Merger & Acquisition Analysts

Companies featured in the report
- Actar AB
- Adenosine Therapeutics
- Boehringer Ingelheim Pharmaceuticals
- Cadus Pharmaceutical
- Cambridge Biotechnology Ltd.
- Can-Fite Biopharma Ltd.
- CV Therapeutics
- Aderis Pharmaceuticals (Discovery Therapeutics)
- Epigenesis Pharmaceuticals
- Genaissance Pharmaceuticals
- Glaxo Group Ltd.
- Hoffmann-La Roche
- Kyowa Hakko Kogyo Co Ltd.
- Merckle GMBH
- Nippon Shinyaku Ltd.
- Novo Nordisk A/S
- OSI Pharmaceuticals
- Pfizer Inc.
- Schering
- Shionogi & Co Ltd.
- SmithKline Beecham
- Warner-Lambert Company
- Whitby Research Inc.
- Yamasa Shoyu

For more information visit
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 29, 2005
Previous Article:Mobile Advertising, Brands and Affinity Marketing are Finding Some Acceptance among Consumers in the US Market.
Next Article:More Than 112 Million Consumers Give Thumbs Up to Biometrics; Convenience and Security Drive Enthusiasm According to Survey on ''Changing Behaviors...

Related Articles
Medco Research Announces Clearance of Investigational New Drug Application for MRE0470.
Medco Research Reports 24 Percent Increase in Fully-taxed EPS From Operations of $0.31 for 3Q99.
Discovery Therapeutics Inc. Announces Phase II Trials for ``Treadmill in a Bottle'' -- MRE0470 --.
Caffeine may ward off Parkinson's.
A sticky problem solved.
Mice reveal the off switch for inflammation. (Science News of the week).
Chemvalet Introduces New Competitive Intelligence Report: Patent Analysis of Adenosine A2A Receptor Agonists.
Research and Markets: Patent Analysis of Adenosine A2A Receptor Agonists.
Kyowa Hakko Kogyo Completes Overseas Phase III Clinical Trials for KW-6002, Anti-Parkinson's Disease Agent.
PPAR[alpha] and effects of TCE.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters